New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For THLD;ISRG;GERN;NFLX;ZIOP;ONTY;HWD;XWES;TROX;MRO;HK;STRZA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
07:32 EDTSTRZAUBS to hold a conference
Subscribe for More Information
06:48 EDTNFLXNetflix wants to be 'completely global' within five years, GigaOM reports
Netflix Chief Content Officer Ted Sarandos told investors at the UBS Global Media and Communications Conference that the company wants to be "completely global" and available everywhere in the world before 2020, GigaOM reports. CEO Reed Hastings has previously said that the company could eventually generate up to 80% of its revenue outside the U.S. Reference Link
December 8, 2014
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
10:30 EDTHKHalcon Resources downgraded to Market Perform at BMO Capital (pre-open)
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information
December 7, 2014
16:48 EDTTHLDThreshold Pharmaceuticals announces data from TH-302 study
Threshold Pharmaceuticals announced new preliminary data from the Phase 2 component of an ongoing company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib, Velcade, and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. The median number of prior therapies was 8. The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses were observed in 2 of 7 evaluable patients overall and 2 of 4 evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California.
14:10 EDTTHLDAmerican Society of Hematology to hold a meeting
Subscribe for More Information
December 5, 2014
16:56 EDTNFLXNetflix initiated with a Neutral at UBS
Target $370.
11:23 EDTNFLXOption volume leaders
Subscribe for More Information
10:00 EDTSTRZAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTSTRZAStarz upgraded at Macquarie
Subscribe for More Information
08:25 EDTSTRZAStarz upgraded to Outperform from Neutral at Macquarie
Subscribe for More Information
06:23 EDTGERNGeron volatility flat into American Society Hematology Annual Meeting
Geron December call option implied volatility is at 106, January is at 115, March is at 104; compared to its 26-week average of 106 according to Track Data, suggesting non-directional price movement into 56th American Society Hematology Annual Meeting abstract presentations.
December 4, 2014
16:27 EDTSTRZAOn The Fly: Closing Wrap
Subscribe for More Information
16:24 EDTGERNGeron announces publication of preclinical data on imetelstat
Subscribe for More Information
16:00 EDTNFLXOptions Update; December 4, 2014
Subscribe for More Information
15:58 EDTSTRZAStarz weighs alternate option after failing to find buyer, Bloomberg reports
Subscribe for More Information
15:37 EDTSTRZAStarz fails to find buyers, exploring alternate options, Bloomberg says
Subscribe for More Information
09:45 EDTSTRZACBS has no interest in acquisition of Starz, CNBC's Faber says
CBS (CBS) has no interest in pursuing an acquisition of Starz (STRZA), according to CNBC's David Faber, citing sources.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use